RES-529 for Idiopathic Pulmonary Fibrosis

[vc_row][vc_column][vc_column_text]RES-529 is Restror Genex Corporation’s novel formulation targeting different signal transduction pathways to inhibit cell growth, differentiation, and proliferation. This drug is therapeutically important in treating a wide spectrum of diseases, including cancer related to ophthalmology and dermatology.

History of RES-529

The company’s most recent endeavor included preclinical trials testing the effects of the drug in animal models with idiopathic pulmonary fibrosis (IPF).

The results of this study, titled “The Novel TOR Complex 1/2 Inhibitor RestorGenex 529 (RES-529) Inhibits Human Lung Myofibroblast Differentiation,” were presented at the American Thoracic Society International Conference in Denver, Colorado, in 2015, and displayed both in vitro and in vivo studies involving effects of RES-529 in inhibiting some of the major pathways (PI3K/Akt/mTOR) playing a pivotal role in IPF.

How RES-529 Works

Myofibriloblasts are one of the major contributors to scarring and fibrosis of tissues due to excessive secretion of collagen, and their growth, differentiation, and proliferation. It does so with the help of growth factors like TGF-ß (Transformation Growth Factor Beta) and VEGF (Vascular Endothelial Growth Factor), and pro-inflammatory proteins like TNF-α (Tumor Necrosis Factor alpha) and IL-1β (Interleukin 1 beta).

TGF-ß is responsible for mediating cell-signaling pathways, with PI3K/Akt/mTOR considered the most important. This pathway helps in the synthesis of protein complexes TORC1 and TORC2 (Target of Rifampicin 1 and 2) — the functional complexes of the TOR protein — a regulator for cell growth, nutrition, and metabolism.

RES-529 inhibits the TGF-ß mediated activation of the PI3K/Akt/mTOR pathway, and inhibits differentiation of myofibroblasts. This inhibitory activity, which held the key to its anti-fibrotic potential, was well demonstrated in animal models.

Next Steps for RES-529

Some of the other diseases eyed for clinical trials for RES-529 include age-related macular degeneration (in ophthalmology) and glioblastoma (in oncology).

Note: Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_wp_text]

[/vc_wp_text][/vc_column][vc_column width=”1/2″][vc_wp_rss items=”7″ title=”Read the Latest News About RES-529″ url=””][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][vc_wp_text title=”Sign Up For The Latest News About RES-529:”]

    Your Name (required)

    Your Email (required)


    Your PF Community

    Woman laying down reading

    Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

    View Forums